Navigation Links
Cumberland Pharmaceuticals Appoints Lee Product Director
Date:1/13/2009

NASHVILLE, Tenn., Jan. 13 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. is pleased to announce the appointment of Barry Lee as Product Director. In this role, Mr. Lee will draw upon his 24 years of pharmaceutical sales and marketing experience to lead the prospective launch and commercialization of new products for the company.

(Photo: http://www.newscom.com/cgi-bin/prnh/20090113/CLTU094 )

"We are extremely pleased to welcome Mr. Lee to Cumberland's management team," said A.J. Kazimi, CEO of Cumberland Pharmaceuticals. "As we work to continue to grow the company, we believe Barry's extensive experience and solid track record of success will be extremely valuable in helping Cumberland deliver promising new products to patients who can benefit."

Mr. Lee joins Cumberland from Bayer Healthcare Pharmaceuticals where he held a variety of sales and marketing positions during his 24-year tenure. In addition to leading sales training and development efforts, he oversaw the launch of the company's Yasmin(R) product, which was one of the most successful industry launches of its time, reaching $92 million in net sales its first year on the market. Under his leadership, the product grew to $320 million in net sales over a four-year period. Mr. Lee is a graduate of Texas A & M University.

Cumberland Pharmaceuticals Inc. is a Tennessee-based specialty pharmaceutical company that develops and markets branded, prescription products for targeted physician segments, including hospital acute care and gastroenterology. Cumberland is dedicated to providing innovative products that improve quality of care for patients. For more information, please visit the Cumberland Pharmaceuticals web site at www.cumberlandpharma.com.


'/>"/>
SOURCE Cumberland Pharmaceuticals Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Neurotech Announces the Opening of Its GMP Manufacturing Facility in Cumberland, Rhode Island
2. Cumberland Pharmaceuticals Taps Industry Veteran for Key Executive Position
3. Genesis Pharmaceuticals Appoints KPMG to Help Develop a SOX 404 Compliance Program
4. Keryx Biopharmaceuticals to Present at the J.P. Morgan 27th Annual Healthcare Conference
5. Alseres Pharmaceuticals, Inc. Announces $1 Million Financing
6. Amylin Pharmaceuticals Highlights 2009 Value Creation Opportunities
7. Sunesis Pharmaceuticals Provides Year-End Clinical Update on Voreloxin
8. MAP Pharmaceuticals Provides Update on Progress of Two Phase 3 Clinical Programs
9. Endo Pharmaceuticals to Present at the J.P. Morgan 27th Annual Healthcare Conference
10. AcelRx Pharmaceuticals Hires Roman Skowronski, M.D., Ph.D. as Vice President of Clinical Development
11. Arena Pharmaceuticals to Present at the 27th Annual J.P. Morgan Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... HOUSTON , June 23, 2016 ... agreement with the Cy-Fair Sports Association to serve ... of the agreement, Houston Methodist Willowbrook will provide ... education and connectivity with association coaches, volunteers, athletes ... partner with the Cy-Fair Sports Association and to ...
(Date:6/23/2016)... FRANCISCO , June 23, 2016   EpiBiome ... has secured $1 million in debt financing from Silicon ... ramp up automation and to advance its drug development ... its new facility. "SVB has been an ... beyond the services a traditional bank would provide," said ...
(Date:6/23/2016)... , June 23, 2016 Apellis Pharmaceuticals, ... 1 clinical trials of its complement C3 inhibitor, ... and multiple ascending dose studies designed to assess ... of subcutaneous injection in healthy adult volunteers. ... either as a single dose (ranging from 45 ...
(Date:6/23/2016)... , ... June 23, 2016 , ... ... exhibiting at the Pennsylvania Convention Center and will showcase its product’s latest features ... will also be presenting a scientific poster on Disrupting Clinical Trials in The ...
Breaking Biology Technology:
(Date:4/28/2016)... First quarter 2016:   , Revenues amounted ... quarter of 2015 The gross margin was 49% (27) ... the operating margin was 40% (-13) Earnings per share ... operations was SEK 249.9 M (21.2) , Outlook   ... M. The operating margin for 2016 is estimated to ...
(Date:4/15/2016)... 2016  A new partnership announced today will ... decisions in a fraction of the time it ... high-value life insurance policies to consumers without requiring ... Force Diagnostics, rapid testing (A1C, Cotinine and HIV) ... pressure, weight, pulse, BMI, and activity data) available ...
(Date:3/31/2016)... 31, 2016   ... the "Company") LegacyXChange is excited to release ... soon to be launched online site for trading 100% ... ) will also provide potential shareholders a sense of ... to an industry that is notorious for fraud. The ...
Breaking Biology News(10 mins):